Glenmark Life Sciences Ltd.

870.05 -6.85 ▼-0.8%

29 February 2024, 04:01:00 PM
Volume: 14,898

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.glenmarklifesciences.com
Market Cap 10,660.48 Cr.
Enterprise Value(EV) 10,301.34 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 42.38 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 20.53 Trailing Twelve Months Ending 2023-12
Industry PE 41.39 Trailing Twelve Months Ending 2023-12
Book Value / Share 204.89 Trailing Twelve Months Ending 2023-12
Price to Book Value 4.25 Calculated using Price: 870.05
Dividend Yield 2.41 Period Ending 2023-03
No. of Shares Subscribed 12.25 Cr. 122,527,172 Shares
FaceValue 2
About Glenmark Life Sciences Ltd.
The company is in the business of making high-quality drugs by unlocking the possibilities of science.

Glenmark Life Sciences Ltd. Delivery

Delivered Qty
Traded Qty

Glenmark Life Sciences Ltd. Performance

1 Day
-0.78%
1 Week
-0.50%
1 Month
+3.73%
3 Month
+38.49%
6 Month
+40.83%
1 Year
+132.26%
2 Year
+89.82%
5 Year
10 Year

Glenmark Life Sciences Ltd. Fundamental Ratios

6 years 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 0 451.05 127.84 60.91 29.87 22.33
Return on Capital Employed (%) 0 527.74 185.6 96.75 42.24 30.01
Return on Assets (%) -510.59 26.51 19.56 17.82 16.57 15.43

Glenmark Life Sciences Ltd. Balance Sheet

Particulars 7 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds -1 88 402 753 2,054 2,138 2,392
Non Curr. Liab. 7 16 23 33 60 62
Curr. Liab. 1 1,380 1,307 1,445 747 1,023 499
Minority Int.
Equity & Liab. 0 1,475 1,726 2,221 2,834 3,220 2,953
Non Curr. Assets 545 565 598 706 852 876
Curr. Assets 0 931 1,160 1,623 2,127 2,369 2,077
Misc. Exp. not W/O
Total Assets 0 1,475 1,726 2,221 2,834 3,220 2,953

Glenmark Life Sciences Ltd. Profit and Loss

Particulars 7 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 0 886 1,537 1,885 2,123 2,161 2,368
Other Income 1 12 1 15 29 12
Total Income 0 887 1,549 1,886 2,138 2,190 2,380
Total Expenditure 0 -639 -1,065 -1,294 -1,507 -1,519 -1,629
PBIDT 0 248 484 592 631 671 751
Interest -1 -34 -88 -28 -1 -1
Depreciation -19 -29 -33 -38 -42 -50
Taxation 0 -33 -108 -119 -146 -162 -180
Exceptional Items
PAT 0 196 313 352 419 467 519
Adjusted EPS -8 18 29 33 34 38 42

Glenmark Life Sciences Ltd. Cash Flow

Particulars 6 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 10 195 388 598 313
Cash Fr. Inv. -9 -51 -69 -122 -154
Cash Fr. Finan. 0 1 -137 -214 -79 -388
Net Change 0 2 8 106 397 -228
Cash & Cash Eqvt 0 2 10 116 512 284

Glenmark Life Sciences Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 82.85 82.85 82.85 82.85 82.85 82.85 82.85 82.85 82.85
Public 17.15 17.15 17.15 17.15 17.15 17.15 17.15 17.15 17.15
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.47 9.47

Glenmark Life Sciences Ltd. Announcements

Wed, 14 Feb 2024
Updates on Open Offer
DAM Capital Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Offer Opening Public Announcement under Regulation 18(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended ("SEBI (SAST) Regulations") and Corrigendum to the Detailed Public Statement and the Letter of Offer for the attention of the Public Shareholders of Glenmark Life Sciences Ltd ("Target Company").
Tue, 13 Feb 2024
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
We are enclosing herewith Monitoring Agency Report for the quarter ended 31st December 2023.
Mon, 12 Feb 2024
Recommendations Of The Committee Of Independent Directors Under Regulation 26(7) Of The SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011
Please find attached herewith newspaper publications of Recommendation of the Committee of Independent Directors under Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011

Glenmark Life Sciences Ltd. Technical Scans

Wed, 28 Feb 2024
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week High Zone Close Within 52 Week High Zone

Glenmark Life Sciences Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 377,475.37 1,577.95 +0.3%
Cipla Ltd. 119,187.32 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. 107,206.64 6,424.25 -0.1%
Zydus Lifesciences Ltd. 94,418.40 941.90 +1.0%
Divi's Laboratories Ltd. 93,236.55 3,489.10 -0.7%
Apollo Hospitals Enterprise Ltd. 91,390.97 6,105.90 -3.9%
Torrent Pharmaceuticals Ltd. 88,302.11 2,666.80 +2.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 42.38 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-12 32.14 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.51 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.75 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-12 67.42 3,489.10 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.78 6,105.90 -3.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 59.10 2,666.80 +2.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.05 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-12 4.60 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.99 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.86 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-12 7.15 3,489.10 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.53 6,105.90 -3.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.35 2,666.80 +2.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 0.02 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,489.10 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,105.90 -3.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,666.80 +2.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,489.10 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,105.90 -3.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,666.80 +2.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,489.10 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,105.90 -3.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,666.80 +2.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,489.10 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,105.90 -3.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,666.80 +2.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,577.95 +0.3%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,480.35 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,424.25 -0.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 941.90 +1.0%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,489.10 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,105.90 -3.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,666.80 +2.2%

Glenmark Life Sciences Ltd. FAQ's

What is Glenmark Life Scienc share price?

Can I buy Glenmark Life Scienc shares now?

What is the Dividend Yield of Glenmark Life Scienc?

What is the Market Cap of Glenmark Life Scienc?

What are the key metrics to analyse Glenmark Life Scienc?

What is the 52 Week High and Low of Glenmark Life Scienc?

What is the trend of Glenmark Life Scienc share price?